Drugs / Uprosertib
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01935973 | Sep 2013 → Sep 2015 | endometrial clear cell adenocarcinoma, endometrial mixed adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01266954 | Jun 2010 → Sep 2011 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01138085 | May 2010 → Nov 2014 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00920257 | Jun 2009 → Apr 2013 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01902173 | Oct 2013 → May 2018 | cutaneous melanoma, hematopoietic and lymphoid cell neoplasm, metastatic malignant neoplasm, metastatic melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT01979523 | Nov 2013 → Sep 2017 overdue | uveal melanoma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 2 | NCT01989598 | Oct 2013 → Aug 2019 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01964924 | Oct 2013 → Jan 2017 | invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01958112 | Oct 2013 → Nov 2017 | cervical cancer | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01907815 | Oct 2013 → Jan 2016 | acute myeloid leukemia | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01941927 | Sep 2013 → Oct 2014 | melanoma | Adil Daud | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Uprosertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01979523 ↗ |
| Known as | Akt inhibitor gsk-2141795 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137336 ↗ |
| Known as | GSK 2141795 | “GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor.” NCT01941927 ↗ |
| Known as | GSK-2141795C | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137336 ↗ |
| Action | Inhibit | “GSK2141795 is an oral AKT inhibitor.” NCT00920257 ↗ |
| Modality | Small molecule | — CHEMBL3137336 ↗ |
| Route | Oral | “GSK2141795 is an oral AKT inhibitor.” NCT00920257 ↗ |
| Target | AKT1 | “GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding...” NCT01941927 ↗ |
| Target | AKT2 | “GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding...” NCT01941927 ↗ |
| Target | AKT3 | “GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding...” NCT01941927 ↗ |